109 related articles for article (PubMed ID: 12396603)
1. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
Gallo RC; Burny A; Zagury D
DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
[TBL] [Abstract][Full Text] [Related]
4. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid.
Le Buanec H; Lachgar A; Bizzini B; Zagury JF; Rappaport J; Santagostino E; Muça-Perja M; Gringeri A
Biomed Pharmacother; 1998; 52(10):431-5. PubMed ID: 9921411
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
6. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.
Zagury D; Lachgar A; Chams V; Fall LS; Bernard J; Zagury JF; Bizzini B; Gringeri A; Santagostino E; Rappaport J; Feldman M; Burny A; Gallo RC
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3851-6. PubMed ID: 9520456
[TBL] [Abstract][Full Text] [Related]
8. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
Gallo RC
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
[No Abstract] [Full Text] [Related]
9. Biological treatment approaches, including Tat toxoid vaccine: interview with Robert Gallo, M.D. Interview by John S. James.
Gallo R
AIDS Treat News; 1999 Sep; (No 327):1-5. PubMed ID: 11366583
[TBL] [Abstract][Full Text] [Related]
10. Repair of the in vitro HIV-1-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-alpha interferon and anti-Tat antibodies.
Lachgar A; Bernard J; Bizzini B; Astgen A; Le Coq H; Fouchard M; Chams V; Feldman M; Burny A; Zagury JF
Biomed Pharmacother; 1996; 50(1):13-8. PubMed ID: 8672726
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
[TBL] [Abstract][Full Text] [Related]
12. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
[TBL] [Abstract][Full Text] [Related]
13. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha.
Lapenta C; Santini SM; Logozzi M; Spada M; Andreotti M; Di Pucchio T; Parlato S; Belardelli F
J Exp Med; 2003 Jul; 198(2):361-7. PubMed ID: 12874266
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
15. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
16. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
17. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
18. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Tat-based vaccines: from basic science to clinical trials.
Fanales-Belasio E; Cafaro A; Cara A; Negri DR; Fiorelli V; Butto S; Moretti S; Maggiorella MT; Baroncelli S; Michelini Z; Tripiciano A; Sernicola L; Scoglio A; Borsetti A; Ridolfi B; Bona R; Ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Vardas E; Magnani M; Laguardia E; Caputo A; Titti F; Ensoli B
DNA Cell Biol; 2002 Sep; 21(9):599-610. PubMed ID: 12396602
[TBL] [Abstract][Full Text] [Related]
20. Tat toxoid as a component of a preventive vaccine in seronegative subjects.
Gringeri A; Santagostino E; Muça-Perja M; Le Buanec H; Bizzini B; Lachgar A; Zagury JF; Rappaport J; Burny A; Gallo RC; Zagury D
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):371-5. PubMed ID: 10096581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
